EXTON, Pa., April 24 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that two-thirds of surveyed U.S. rheumatologists believe that—at three months post launch—initiations of Pfizer's Xeljanz in the rheumatoid arthritis (RA) treatment algorithm will follow methotrexate failure/intolerance and at least two biologic failures. Only one in ten surveyed physicians currently plan to use the treatment prior to biologic initiation.
According to the BioTrends Research Group report entitled LaunchTrends®: Xeljanz, Wave 2, surveyed rheumatologists report that among their patients currently treated with Xeljanz, 87 percent were switched from a biologic agent, while the remaining 13 percent of current Xeljanz patients were biologic naive prior to initiation. When questioned directly about agents at risk for displacement, nearly one-quarter of rheumatologists believe that Xeljanz is most likely to displace Genentech's Actemra with regard to RA patient share.
The recently published report also reveals that at three months post launch, approximately one-third of surveyed rheumatologists report prescribing Xeljanz in an average of three RA patients. Although rheumatologists anticipate Xeljanz trial rates to increase in the future, four percent claim that they will never use Xeljanz, primarily due to efficacy concerns and side effects.
"The percent of rheumatologists who have used Xeljanz in at least one patient has remained around one-third since the first wave of research, at one-month post launch," said BioTrends Research Group Associate Director of Immunology
|SOURCE BioTrends Research Group|
Copyright©2012 PR Newswire.
All rights reserved